Autolus Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-220.66	-208.38	-148.84	-142.1
Depreciation & Amortization	7.72	6.57	7.36	8.37
Other Amortization	-	-	0.07	0.09
Loss (Gain) From Sale of Assets	0.22	3.79	0.52	0.67
Asset Writedown & Restructuring Costs	0.41	0.38	-	-
Loss (Gain) From Sale of Investments	-1.25	-	-	-
Stock-Based Compensation	15.47	11.2	12.01	9.94
Other Operating Activities	15.47	40.56	16.04	4.76
Change in Inventory	-4.23	-	-	-
Change in Accounts Payable	1.59	-0.51	0.02	-1.82
Change in Other Net Operating Assets	-21.02	0.8	0.51	2.23
Operating Cash Flow	-206.27	-145.59	-112.31	-117.86
Capital Expenditures	-22.08	-10.99	-10.84	-8.86
Sale (Purchase) of Intangibles	-12.74	-	-	-
Investment in Securities	-359.73	-	-	-
Investing Cash Flow	-394.55	-10.99	-10.84	-8.86
Issuance of Common Stock	550.58	0.03	163.97	246.03
Other Financing Activities	38.98	-0.91	59.64	38.04
Financing Cash Flow	589.55	-0.88	223.61	284.06
Foreign Exchange Rate Adjustments	-0.26	15.03	-28.38	-0.75
Net Cash Flow	-11.53	-142.43	72.09	156.59
Free Cash Flow	-228.35	-156.57	-123.15	-126.72
Free Cash Flow Margin	-2256.38%	-9221.02%	-1936.31%	-5438.54%
Free Cash Flow Per Share	-0.90	-0.90	-1.30	-1.76
Cash Income Tax Paid	2.39	0.55	0.47	0.36
Levered Free Cash Flow	-187.04	-125.13	-75.76	-77.76
Unlevered Free Cash Flow	-181.23	-96.97	-70.2	-77.07
Change in Working Capital	-23.66	0.29	0.54	0.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.